期刊
NUCLEIC ACID THERAPEUTICS
卷 30, 期 5, 页码 289-298出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/nat.2019.0833
关键词
CD44; DNA aptamer; cancer; leukemia
资金
- Preludium Grant from the National Science Centre, Poland [UMO-2012/05/N/NZ3/00299]
- Maestro Grant from the National Science Centre, Poland [UMO-2012/06/A/ST5/00224]
- Opus Grant from the National Science Centre, Poland [UMO-2017/25/B/NZ1/00827]
CD44 is a type I transmembrane glycoprotein interacting with a number of extracellular components, including hyaluronic acid (HA). CD44-HA axis is involved in a variety of processes, including adhesion, migration, differentiation, trafficking, and others. CD44 is overexpressed in several cancers where binding of HA induces signal transduction leading to activation of antiapoptotic proteins and factors linked to drug resistance. As such, CD44 has been implicated in cancer growth, progression, and metastasis. It has been convincingly demonstrated that blocking CD44-HA interaction decreases cancer cell survival and metastasis. In this study, using in vitro selection, we have developed DNA aptamers recognizing a HA-binding domain of CD44 with high affinity and specificity. The aptamers bind to CD44 with nanomolar affinities and efficiently inhibit the growth of leukemic cancer cells characterized by high expression of CD44. The selectivity is demonstrated by an irrelevant effect on cells characterized by low CD44 levels. The obtained aptamers broaden the existing landscape of potential approaches to the development of antitumor strategies based on inhibition of the CD44 axis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据